Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
4basebioLSE:4BB 57 Cash Ratio is 6.30 as of Dec. 2025, which is 0% above its 10-year median of 6.29. GuruFocus rates LSE:4BB with a GF Score™ of 57/100 and a GF Value™ of £29.10 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,379 Biotechnology companies, 4basebio ranks better than 68.89% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
4basebio Cash Ratio Related Terms
4basebio Cash Ratio Historical Data
* Premium members only.
The historical data trend for 4basebio's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:4BB vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, 4basebio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4basebio Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4basebio's Cash Ratio distribution charts can be found below:
* The bar in red indicates where 4basebio's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4basebio (LSE:4BB) has a Cash Ratio of 6.30 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on 4basebio and its competitors. This is near median its historical median of 6.29. Over the past decade, 4basebio's Cash Ratio has ranged from 0.14 to 18.45. According to the industry distribution chart, 4basebio ranks #429 out of 1379 companies in the Biotechnology industry, placing it in the top 31.1%.
Is 4basebio's Cash Ratio too high?
4basebio's current Cash Ratio of 6.30 is near median its 10-year median of 6.29. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 18.45. The Biotechnology industry median Cash Ratio is 2.97. 4basebio's value of 6.30 is 112.1% above this industry median. Based on the distribution chart, 4basebio ranks #429 out of 1379 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 4basebio has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4basebio's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 4basebio ranks #429 out of 1379 companies for Cash Ratio. This puts 4basebio in the upper half of its industry. The industry median Cash Ratio is 2.97. 4basebio's value of 6.30 is 112.1% above this benchmark. Historically, 4basebio's own Cash Ratio has ranged from 0.14 to 18.45 over the past decade. While the company's 10-year median is 6.29 vs. the industry median of 2.97, 4basebio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.97, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4basebio's current Cash Ratio of 6.30 is 112.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on 4basebio and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4basebio's current Cash Ratio is 6.30, which is near median its own 10-year median of 6.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4basebio stock overvalued right now?
Based on GuruFocus' analysis, 4basebio (LSE:4BB) is currently considered Possible Value Trap. The stock's GF Value™ is £29.10, compared to a current price of £4.75 — trading 83.7% below its estimated fair value. The current Cash Ratio is 6.30, which is near median its 10-year median of 6.29 and 112.1% above the Biotechnology industry median of 2.97. 4basebio's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For 4basebio (LSE:4BB), the current Cash Ratio is 6.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4basebio (LSE:4BB) Overvalued in 2026?
Based on GuruFocus' analysis, 4basebio stock appears to be undervalued.
The current stock price of £4.75 is trading 83.7% below its estimated GF Value™ of £29.10.
GuruFocus considers 4basebio to be Possible Value Trap.
Key valuation signals for LSE:4BB:
Cash Ratio: 6.30 (near median its 10-year median of 6.29)
GF Value™: £29.10 vs. price of £4.75 (83.7% below fair value)
Industry Position: 112.1% above the Biotechnology median (#429 of 1379)
No single metric tells the full story. See the LSE:4BB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
57GF Score
Get the complete analysis for LSE:4BB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:4BB has been successfully added to your 
